Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NSA-789 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| placebo | PLACEBO_COMPARATOR | - |
| NSA-789 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| NSA-789 | DRUG | - |
| placebo | OTHER | - |
Inclusion Criteria * Men or women aged 18 - 50 years (healthy subjects) or greater than 55 years old (subjects with Alzheimer's Disease) * Women must be surgically sterile or postmenopausal * Subjects with Alzheimer's Disease must be generally healthy, but may have a stable, chronic illness if well...
Top 20 of 24 competitors
NSA-789 is an investigational small molecule being studied for Alzheimer disease and for use in healthy volunteers. It is in Phase 1 clinical development and is not approved by the FDA. The drug is being evaluated for safety, tolerability, and pharmacokinetics in early-stage trials.
NSA-789 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development for Alzheimer disease and healthy volunteer studies.
NSA-789 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. All completed trials for NSA-789 are Phase 1 studies evaluating safety, tolerability, and pharmacokinetics in healthy subjects and in Alzheimer disease patients.
NSA-789 has completed three Phase 1 clinical trials. NCT00619736 evaluated safety and pharmacokinetics in healthy Japanese male subjects. NCT00633048 studied safety and tolerability in healthy adults in the United States. NCT00795730 assessed multiple-dose safety and tolerability in Alzheimer disease patients and healthy subjects.
NSA-789 is the drug name used in clinical trials registered with ClinicalTrials.gov. No alternative names for NSA-789 have been disclosed in the trial records, and the drug is identified solely by this designation in the studies conducted by Pfizer.